AR

Accuray IncNASDAQ ARAY Stock Report

Last reporting period 30 Sep, 2024

Updated 20 Nov, 2024

Last price

Market cap $B

0.177

Micro

Exchange

XNAS - Nasdaq

ARAY Stock Analysis

AR

Uncovered

Accuray Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-27/100

Low score

Market cap $B

0.177

Dividend yield

Shares outstanding

95.495 B

Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells, and supports solutions that are designed to deliver radiation treatments. Its solutions are designed to advance patient care during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, the Company also provides services, which include post-contract customer support (warranty period services and post warranty services), installation services, training, and other professional services.

View Section: Eyestock Rating